Search alternatives:
mg decrease » _ decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
ms decrease » _ decrease (Expand Search), nn decrease (Expand Search), use decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 ms » 50 mg (Expand Search), 50 mm (Expand Search)
Showing 361 - 380 results of 65,625 for search '(( 5 ((((mg decrease) OR (mean decrease))) OR (a decrease)) ) OR ( 50 ms decrease ))', query time: 1.00s Refine Results
  1. 361
    Total viable immune cells and macrophages decrease acutely while neutrophils and macrophage increase at day 30 in parotid glands after 5Gy IR.

    Total viable immune cells and macrophages decrease acutely while neutrophils and macrophage increase at day 30 in parotid glands after 5Gy IR. by Jordan A. Gunning (18143970)

    Published 2024
    Save to List
    Saved in:
  2. 362
    Relative fixation duration distribution.

    Relative fixation duration distribution. by Junhui Kim (18575083)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  3. 363
    Smoothed density histograms of simulated cumulative RCS exposures of increasing mean values.

    Smoothed density histograms of simulated cumulative RCS exposures of increasing mean values. by Patrick Howlett (2612374)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  4. 364
    Fig 5 -

    Fig 5 - by Saeed El-Ashram (710370)

    Published 2021
    Save to List
    Saved in:
  5. 365
    Fig 5 -

    Fig 5 - by Rajnish Prakash Singh (2847608)

    Published 2022
    Save to List
    Saved in:
  6. 366
    Fig 5 -

    Fig 5 - by Wenping Dong (3854437)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  7. 367
    TBEV-induced translational arrest results in the decreased protein levels of GAPDH, HPRT1, and viperin.

    TBEV-induced translational arrest results in the decreased protein levels of GAPDH, HPRT1, and viperin. by Martin Selinger (3195987)

    Published 2019
    Save to List
    Saved in:
  8. 368
    Cycloheximide (CHX) treatment decreases production of rRNA transcripts by POLR1 and POLR3.

    Cycloheximide (CHX) treatment decreases production of rRNA transcripts by POLR1 and POLR3. by Martin Selinger (3195987)

    Published 2019
    “…<p>(A) DAOY cells were treated with CHX (100 μg/ml) for either 6 or 14 hours; for metabolic RNA labelling, 5-EU was added 2 hours before the sample collection. …”
    Save to List
    Saved in:
  9. 369
    Effects of SNPs on the Protein Stability, Increasing or Decreasing.

    Effects of SNPs on the Protein Stability, Increasing or Decreasing. by Mirza Jawad Ul Hasnain (8351388)

    Published 2020
    Save to List
    Saved in:
  10. 370
    Loss of nsp14-ExoN activity decreases recombination frequency and alters recombination junction patterns across the genome.

    Loss of nsp14-ExoN activity decreases recombination frequency and alters recombination junction patterns across the genome. by Jennifer Gribble (10005444)

    Published 2021
    Save to List
    Saved in:
  11. 371
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 372
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 373
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 374
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 375
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 376
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 377
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 378
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 379
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 380
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: